230 related articles for article (PubMed ID: 37510809)
1. JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases.
Melki I; Frémond ML
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510809
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis.
Miserocchi E; Giuffrè C; Cornalba M; Pontikaki I; Cimaz R
Clin Rheumatol; 2020 Mar; 39(3):847-851. PubMed ID: 31897953
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
4. Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
Thomas J; Kuthyar S; Shantha JG; Angeles-Han ST; Yeh S
Ann Eye Sci; 2021 Jun; 6():. PubMed ID: 34131629
[TBL] [Abstract][Full Text] [Related]
5. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).
Verweyen EL; Schulert GS
Rheumatology (Oxford); 2022 Mar; 61(3):926-935. PubMed ID: 34459891
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
[TBL] [Abstract][Full Text] [Related]
7. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.
Kostik MM; Raupov RK; Suspitsin EN; Isupova EA; Gaidar EV; Gabrusskaya TV; Kaneva MA; Snegireva LS; Likhacheva TS; Miulkidzhan RS; Kosmin AV; Tumakova AV; Masalova VV; Dubko MF; Kalashnikova OV; Aksentijevich I; Chasnyk VG
Front Pediatr; 2022; 10():820586. PubMed ID: 35211430
[TBL] [Abstract][Full Text] [Related]
8. Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward.
Bagri NK; Chew C; Ramanan AV
Paediatr Drugs; 2023 Nov; 25(6):635-647. PubMed ID: 37775678
[TBL] [Abstract][Full Text] [Related]
9. Regulation of JAK/STAT signal pathway by miR-21 in the pathogenesis of juvenile idiopathic arthritis.
Li HW; Zeng HS
World J Pediatr; 2020 Oct; 16(5):502-513. PubMed ID: 31641939
[TBL] [Abstract][Full Text] [Related]
10. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
Ramanan AV; Dick AD; Benton D; Compeyrot-Lacassagne S; Dawoud D; Hardwick B; Hickey H; Hughes D; Jones A; Woo P; Edelsten C; Beresford MW;
Trials; 2014 Jan; 15():14. PubMed ID: 24405833
[TBL] [Abstract][Full Text] [Related]
11. Treatment of juvenile idiopathic arthritis: a revolution in care.
Stoll ML; Cron RQ
Pediatr Rheumatol Online J; 2014; 12():13. PubMed ID: 24782683
[TBL] [Abstract][Full Text] [Related]
12. Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.
Golhen K; Winskill C; Yeh C; Zhang N; Welzel T; Pfister M
Front Pediatr; 2022; 10():909118. PubMed ID: 35799700
[TBL] [Abstract][Full Text] [Related]
13. Subtype frequencies, demographic features, and remission rates in juvenile idiopathic arthritis - 265 cases from a Turkish center.
Çakan M; Aktay-Ayaz N; Keskindemirci G; Ekinci DY; Karadağ ŞG
Turk J Pediatr; 2017; 59(5):548-554. PubMed ID: 29745116
[TBL] [Abstract][Full Text] [Related]
14. Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis.
Saxena N; Aggarwal A; Misra R
J Rheumatol; 2005 Jul; 32(7):1349-53. PubMed ID: 15996076
[TBL] [Abstract][Full Text] [Related]
15. The necessity, efficacy and safety of biologics in juvenile idiopathic arthritis.
Cakan M; Ayaz NA; Karadag SG; Tanatar A
North Clin Istanb; 2020; 7(2):118-123. PubMed ID: 32259032
[TBL] [Abstract][Full Text] [Related]
16. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis.
Kenawy N; Cleary G; Mewar D; Beare N; Chandna A; Pearce I
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):297-300. PubMed ID: 20922440
[TBL] [Abstract][Full Text] [Related]
17. Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype.
Clarke SLN; Robertson L; Rice GI; Seabra L; Hilliard TN; Crow YJ; Ramanan AV
Pediatr Rheumatol Online J; 2020 May; 18(1):37. PubMed ID: 32398023
[TBL] [Abstract][Full Text] [Related]
18. Decreased frequency of allergy in juvenile idiopathic arthritis: Results of a case-control study.
Avar-Aydin PO; Nepesov S; Barut K; Sahin S; Adrovic A; Cokugras HC; Kasapcopur O
Mod Rheumatol; 2021 May; 31(3):697-703. PubMed ID: 32815440
[TBL] [Abstract][Full Text] [Related]
19. Management of Children with Juvenile Idiopathic Arthritis.
Viswanathan V; Murray KJ
Indian J Pediatr; 2016 Jan; 83(1):63-70. PubMed ID: 26639461
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for juvenile arthritis: agents in early clinical trials.
Rosina S; Giancane G; Ruperto N
Expert Opin Investig Drugs; 2022 Oct; 31(10):1109-1124. PubMed ID: 36066506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
